Suspected Adverse Drug Reactions of Angiotensin 11 converting enzyme inhibitors reported to BoMRA
Botswana Medicines Regulatory Authority (BoMRA) continues to monitor safety of medicinal products registered in Botswana. One of the key activities is to advocate for adverse drug reactions (ADRs) reporting, assessment, and analysis. BoMRA has analyzed safety reports associated with angiotensin converting enzyme inhibitors (ACEIs) received between 1st April 2019 and 28th February 2023.
Bedaquiline-containing regimenscardiac adverse events
Bedaquiline is an antimycobacterial drug used for the treatment of pulmonary multidrug resistant tuberculosis.Bedaquiline inhibits adenosine 5′-triphosphate (ATP) synthesis, a process that is crucial to the growth of mycobacteriumand to its survival in its non-growing dormant state. Bedaquiline is recommended for the treatment of pulmonaryMultidrug Resistant Tuberculosis (MDR-TB) and Rifampicin Resistant-Tuberculosis medicines (RR-TB) by world […]